Last edition
News about "Oncology"
Avacta Reports Early Clinical Validation of AVA6103 in FOCUS-01 Trial
Avacta’s early FOCUS-01 data provide clinical validation for AVA6103 and support further evaluation of its pre|CISION tumour-activated PDC platform.
Oncology | 21/09/2026 | By News Bureau | 972
Gilead Sciences Opens 182,000-Sq-Ft Research Centre at Foster City Headquarters
Gilead Sciences has opened a 182,000-square-foot research centre in Foster City, expanding its capabilities in oncology, inflammation and research data science.
Oncology | 10/09/2026 | By News Bureau
Astellas Pharma’s agreement aims to improve medicine affordability, strengthen critical drug supply chains and support continued investment in innovative therapies.
Oncology | 03/09/2026 | By Akanki | 137
RedHill Biopharma Divests Talicia Business to Apotex for USD 18 Million Upfront
RedHill Biopharma has divested its 70 percent interest in Talicia to Apotex in a deal valued at up to USD 53 million, including potential sales milestones.
Oncology | 01/09/2026 | By News Bureau
Can-Fite BioPharma Secures Australian Patent for Namodenoson in Advanced Metastatic Cancer
Can-Fite BioPharma has secured an Australian patent covering the use of Namodenoson for advanced metastatic cancer, strengthening intellectual property protection as the drug advances through late-stage clinical development for liver and pancreatic cancers.
Oncology | 15/07/2026 | By News Bureau | 137
New patient-derived xenograft study demonstrates strong synergy between GLIX1 and PARP inhibitors in HR-proficient ovarian cancer, paving the way for expanded clinical evaluation in Phase 1/2a trials.
Oncology | 09/07/2026 | By News Bureau | 118
Worldwide Clinical Trials Completes Acquisition of Oncology-Focused CRO Catalyst Clinical Research
Worldwide Clinical Trials strengthens its oncology and early-phase research capabilities following the completion of its acquisition of Catalyst Clinical Research.
Oncology | 17/02/2026 | By News Bureau | 284
FDA Grants Orphan Drug Status to HanchorBio's HCB101 for Gastric Cancer
The Orphan Drug Status designation to HanchorBio supports development of next-generation CD47–SIRPα immunotherapy for advanced gastric adenocarcinoma across HER2-positive and HER2-negative subtypes.
Oncology | 16/02/2026 | By News Bureau | 184
Innovent Biologics and Eli Lilly Forge Strategic Collaboration in Oncology and Immunology
Innovent Biologics will receive USD 350 million upfront and up to USD 8.5 billion in milestones under a new global development pact, with Lilly securing ex-Greater China rights to novel oncology and immunology programmes.
Oncology | 10/02/2026 | By News Bureau | 211
FIU Researchers Advance Functional Precision Medicine for Hard to Treat Cancers
FIU researchers are advancing functional precision medicine for hard-to-treat cancers, with new funding accelerating drug sensitivity testing to identify personalized, effective therapies beyond conventional genetic approaches.
Oncology | 22/01/2026 | By News Bureau | 276
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy